When Desire Disappears: Understanding the Hormonal Picture
Low libido affects an estimated 40% of women at some point in their lives, with prevalence increasing significantly during perimenopause and postmenopause. Despite its prevalence, low libido in women is frequently undertreated, dismissed as psychological, or attributed to relationship factors when the underlying driver is hormonal and directly treatable.
The hormonal causes of low libido in women are multiple and often simultaneous — which is why treatment of any single hormone in isolation frequently produces incomplete results. A comprehensive evaluation is essential for effective treatment.
Want to talk it through with our team?
Book a free 15-minute video consult. Start for $247 — includes your first doctor visit. No membership.
Testosterone Deficiency: The Primary Driver
Testosterone is the most direct hormonal driver of libido in women, as in men. Desire — the spontaneous or responsive motivation to initiate or engage in sexual activity — is primarily androgen-mediated in women. Studies consistently show that free testosterone levels correlate strongly with sexual desire, arousal, and responsiveness in women across reproductive ages, perimenopause, and postmenopause.
Testosterone declines throughout the female reproductive lifespan: from peak levels in the mid-20s, declining approximately 50% by menopause, and then dropping further as ovarian androgen production ceases. Women who undergo oophorectomy (surgical removal of ovaries) experience immediate, dramatic testosterone loss and consistently report one of the most severe libido impairments of any group in sexual medicine research.
Low-dose testosterone therapy — restoring free testosterone to premenopausal young adult female ranges — is the most evidence-based pharmacological treatment for low libido in women with documented androgen deficiency. The International Society for the Study of Women’s Sexual Health (ISSWSH) and the International Menopause Society both endorse testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women based on high-quality evidence.
Estrogen Deficiency: The Physical Barrier
While testosterone governs desire, estrogen governs the physical experience of sex. Estrogen deficiency causes genitourinary syndrome of menopause (GSM): vaginal atrophy with reduced mucosal thickness, loss of lubrication, fragility, and often dyspareunia (pain during sex). When intercourse is painful, avoidance is not low libido — it is a protective physiological response. Treating libido without addressing GSM produces partial results at best.
Local vaginal estrogen (cream, suppository, ring, or tablet) is the most effective treatment for GSM. It is safe, minimally absorbed systemically, and appropriate even for women who cannot or choose not to use systemic HRT. Relief typically begins within 2–4 weeks, with full tissue restoration over 3 months.
Progesterone and Mood
Progesterone deficiency contributes to anxiety, mental fatigue, and emotional dysregulation that reduce interest in intimacy — particularly the desire for physical closeness and emotional availability that supports sexual initiation. While progesterone is not a direct libido hormone, restoring it via oral micronized progesterone often improves the psychological preconditions for desire: reduced anxiety, improved sleep, greater sense of calm and connection.
Thyroid Dysfunction
Hypothyroidism produces fatigue, mood depression, and reduced sensitivity to all pleasurable stimuli — including sexual — through its global effects on neurological function. Low libido in women with undiagnosed or undertreated hypothyroidism typically responds partially or fully to thyroid optimization, even without testosterone therapy.
Cortisol and Stress
Chronic stress elevates cortisol, which directly suppresses the neurological circuits of desire — a hard-wired evolutionary priority mechanism (survival before reproduction). Cortisol also competes with progesterone for receptor binding, compounds progesterone deficiency, and reduces testosterone through pregnenolone steal. Addressing adrenal function is an essential component of comprehensive low libido treatment in women under significant chronic stress.
Low libido in women deserves a complete hormonal evaluation, not dismissal. Call Multigen Wellness at (800) 259-0015 for a comprehensive women’s hormone consultation.
How it works
From your first call to medication at your door.
- AFree 15-minute video consult. We go over your goals, answer your questions, and confirm we can treat you in your state.
- BStart for $247, which includes your first doctor visit.
- CLab work: free with insurance at Quest or any other lab. Book your Quest visit in your patient portal, or take our lab order form to any lab that takes your insurance.
- DDoctor visit: once results are back, meet by video with a dedicated hormone therapy specialist (PAs, NPs and doctors on staff) to review labs and plan medication or therapy.
- EMedication shipped to your door. We bill you for the medication and ship it to your house. See medication prices
What it costs
- No monthly fee, no membership, no commitment.
- $97 per visit, only when needed.
- Prescriptions need lab work and a video visit at least every 90 days.
- Most new patients are seen every 30 days at first.